Otros idiomas Evoke Pharma, Inc.

Acciones

EVOK

US30049G2030

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,45 ^USD	+2,27 %		+1,47 %	-57,16 %

24/04	Transcript : Evoke Pharma, Inc. - Special Call
21/03	Evoke Pharma, Inc. anuncia cambios en el consejo a partir del 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	17/04
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	21/03
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	21/03
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	21/03
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	14/03
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	14/03
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	07/03
Evoke Pharma Announces Closing of $7.5 Million Public Offering	14/02
Evoke Pharma Prices Underwritten Public Offering	09/02
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	09/02
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	30/11
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	27/11
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	27/11
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	22/11
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	15/11
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	14/11
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Evoke Pharma Reports Third Quarter 2023 Financial Results	09/11
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	01/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Evoke Pharma, Inc.

Acciones

EVOK

US30049G2030

Otros idiomas

Filtros